Shots:

• Allergan will divest its brazikumab to AstraZeneca including its global development and commercialization rights while Nestle to acquire complete ownership of Zenpep and will be acquiring Viokace as a part of the same transaction
• The divestiture of two therapies is in conjunction with the ongoing US FTC’s and EC’s approval. The transactions are expected to be completed simultaneously with the pending acquisition whereas AbbVie is expected to complete its pending transaction in Q1’20
• Brazikumab is a mAb targeting IL23 receptor- currently being evaluated in P-IIb/III study for CD & P-IIb for UC while Zenpep is prescription therapy for patients with for exocrine pancreatic insufficiency due to CF and other conditions

Click here ­to­ read full press release/ article | Ref: AbbVie | Image: Livemint